Evidence map›Paper›PMID 31751863›Full record

ArticleParkinsonism & related disorders2019

Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.

Sarah Horn, Hayley Richardson, Sharon X Xie, Daniel Weintraub, Nabila Dahodwala

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parkinsonism & related disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Long-term outcomes with pimavanserin for psychosis in clinical practice.Clinical parkinsonism & related disorders · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sarah HornUniversity of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: Sarah.Horn@uphs.upenn.edu.
Hayley RichardsonUniversity of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: rhayley@pennmedicine.upenn.edu.
Sharon X XieUniversity of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: sxie@pennmedicine.upenn.edu.
Daniel WeintraubUniversity of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: Daniel.Weintraub@uphs.upenn.edu.
Nabila DahodwalaUniversity of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: Nabila.Dahodwala@uphs.upenn.edu.
University of Pennsylvania · US

Funding

UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DETRE, JOHN A · 1991 to 2020
$35.1M
Project IV "Tackling Heterogeneity of Cognitive Trajectory in LBD"U19AG062418 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2019 to 2023
$18.1M
NIA NIH HHS P30 AG010124NIA NIH HHS U19 AG062418
6 · The paper itself

Abstract

introductionPsychosis is common among patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Limited data exist on the most effective therapies.

methodsRetrospective cohort study comparing patients with PD or DLB initiated on quetiapine or pimavanserin for psychosis. Primary outcome was time to discontinuation of pimavanserin or quetiapine using Kaplan-Meier survival analysis. We hypothesized the rate of antipsychotic discontinuation would be lower in the pimavanserin group. Subjects were included if the indication for treatment was psychosis and excluded if there was a history of major mental illness or no follow up data were available.

resultsForty-seven patients were included in the quetiapine cohort and 45 in the pimavanserin cohort. Patients in the pimavanserin cohort were more likely to have a diagnosis of DLB (33% vs. 11%, P = 0.01) and to have been prescribed an antipsychotic previously (62% vs. 6%, P < 0.01); otherwise, the groups were similar. Time to discontinuation analysis, which accounts for efficacy, safety and tolerability, revealed a lower early pimavanserin discontinuation rate and a higher late pimavanserin discontinuation rate (HR < 1 before day 43, HR > 1 after day 43; P = 0.04). There was no difference in mortality in the pimavanserin group compared to the quetiapine group (HR 0.37, 95% CI 0.06 to 2.45; P = 0.88). More individuals had a documented secondary indication for taking quetiapine than pimavanserin (38% vs. 4%; P = 0.001).

conclusionAccounting for efficacy, safety and tolerability, pimavanserin may be more clinically useful for promptly managing psychosis, while quetiapine may confer additional secondary benefits long-term.

Indexed as

AdultAgedAged, 80 and overAntipsychotic AgentsCohort StudiesFemaleHumansLewy Body DiseaseMaleMiddle AgedParkinson DiseasePiperidinesPsychotic DisordersQuetiapine FumarateRetrospective StudiesUreaAntipsychotic AgentspimavanserinPiperidinesQuetiapine FumarateUreaDementia with Lewy bodiesParkinson's diseasePimavanserinPsychosisQuetiapine

Identifiers

PMID31751863
PMCPMC7061324
OpenAlexW2985596483

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.